Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Terri L. Parker, Adam Rosenthal, Vaishali Sanchorawala, Heather J. Landau, Erica L. Campagnaro, Prashant Kapoor, Natalia Neparidze, Saulius Girnius, Patrick Hagen, Emma C. Scott, Antje Hoering, Brian G.M. Durie, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2024-208341

Published: 2024

Journal Articles

Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7831.

https://doi.org/10.1182/blood-2024-204150

Published: 2024

Journal Articles

The Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis

Junmin Song, Shweta Ravindra Deshpande, Yu-Cheng Chang, Cho-Han Chiang, Jaeun Ahn, Ana Yasmin Caceres Lessa, Anushri Soni, Anthony Gonzales, Pei-Lun Lee, Yu Chang, Terri L. Parker, Jennifer Kwan, Kuan-Yu Chi, Michael G. Nanna

Blood (2024) 144 (Supplement 1): 6869.

https://doi.org/10.1182/blood-2024-194867

Published: 2024

Journal Articles

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Patrick Hagen, Surbhi Sidana, Terri L. Parker, Brian A. Walker, Vaishali Sanchorawala, Jeffrey A. Zonder, Taxiarchis Kourelis, Anita D'Souza, Heather J. Landau, Adam Rosenthal, Antje Hoering, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2024) 144 (Supplement 1): 3309.1.

https://doi.org/10.1182/blood-2024-208227

Published: 2024

Journal Articles

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Blood (2024) 144 (11): 1153–1167.

https://doi.org/10.1182/blood.2024024104

Published: 2024

Includes: Supplemental data

Journal Articles

Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Sabrina L. Browning, Allison J. Li, Terri L. Parker, Noffar Bar, Tara Anderson, Erica Stevens, Yuxin Liu, Martin Matthews, Jennifer VanOudenhove, Rebecca Cardone, Qiushi Sun, Robert Hale, Stephanie Halene, Richard Kibbey, Natalia Neparidze

Blood (2023) 142 (Supplement 1): 4774.

https://doi.org/10.1182/blood-2023-186401

Published: 2023

Journal Articles

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Blood (2022) 140 (Supplement 1): 7086–7087.

https://doi.org/10.1182/blood-2022-168109

Published: 2022

Journal Articles

Defining Ferritin Clinical Decision Limits to Improve Diagnosis and Treatment of Iron Deficiency: A Modified Delphi Study

Kanza Naveed, Nicola Goldberg, Eliane Shore, Arti Dhoot, Denise Gabrielson, Zahra Goodarzi, Yulia Lin, Menaka Pai, Natasha A. Pardy, Sue Robinson, Roseann Andreou, Manish Sood, Victoria Price, Ashley Verduyn, Michelle L. Parker, Michael Fralick, Daniel Beriault, Michelle Sholzberg

Blood (2022) 140 (Supplement 1): 11082–11084.

https://doi.org/10.1182/blood-2022-163741

Published: 2022

Journal Articles

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7308–7310.

https://doi.org/10.1182/blood-2022-166325

Published: 2022

Journal Articles

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Talib Dosani, Anna Poteraj, Terri L. Parker, Noffar Bar, Sabrina L. Browning, Elan Gorshein, Tara Anderson, Karl Insogna, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2021-147466

Published: 2021

Journal Articles

Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience

Yuxin Liu, Bohm Kywe, Lake Crawford, Federico Lora, Noffar Bar, Sabrina L. Browning, Elan Gorshein, Terri L. Parker, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2021-146619

Published: 2021

Journal Articles

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

Sabrina L. Browning, MD, Terri L. Parker, MD, Noffar Bar, MD, Tara Anderson, PA, Madhav V. Dhodapkar, MBBS, Stuart Seropian, MD, Alfred Ian Lee, MD PhD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Mina L. Xu, MD, Elan Gorshein, DO, JD, MPH, Ashita Talsania, MCRP, MBBS, Wajih Zaheer Kidwai, MD, David H. Witt, MD, Victor Chang, MD, Andrew Lischuk, MD, Wei Wei, MD PhD, Andrew Haims, MD, Natalia Neparidze, MD

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-136478

Published: 2020

Journal Articles

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Terri L. Parker, MD, Adam Rosenthal, MS, Vaishali Sanchorawala, MD, Heather J Landau, MD, Erica Campagnaro, MD, Prashant Kapoor, MD, Natalia Neparidze, MD, Patrick Hagen, MD, Shayna Sarosiek, MD, Emma C. Scott, MD, Antje Hoering, PhD, Brian G.M. Durie, MD, Saad Z. Usmani, MDMBBS,MBA, Robert Z. Orlowski, MDPhD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-143180

Published: 2020

Journal Articles

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Kishan Patel, BS, Terri L. Parker, MD, Mengyang Di, MD PhD, Noffar Bar, MD, Scott F. Huntington, MD MPH, Smith Giri, MDMS

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-141972

Published: 2020

Journal Articles

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Rory M Shallis, MD, Jan Philipp Bewersdorf, MD, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Thomas Prebet, MD PhD, Steven D. Gore, MD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 1330.

https://doi.org/10.1182/blood-2019-127422

Published: 2019

Journal Articles

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Lohith Gowda, MD MRCP, Karl Hager, PhD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5173.

https://doi.org/10.1182/blood-2019-127162

Published: 2019

Journal Articles

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Jan Philipp Bewersdorf, MD, Rory M Shallis, MD, Autumn Diadamo, BS, Lohith Gowda, MD, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Thomas Prebet, MD PhD, Stephanie Halene, MD, Iris Isufi, MD, Francine M. Foss, MD, Scott F. Huntington, MD MPH, Tae Kon Kim, MD PhD, Manoj M Pillai, MD, Terri L Parker, MD, Natalia Neparidze, MD, Noffar Bar, MD, Stuart Seropian, MD, Alexa J. Siddon, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 5174.

https://doi.org/10.1182/blood-2019-127277

Published: 2019

Journal Articles

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Sabrina L Browning, MD, Terri L Parker, MD, Noffar Bar, MD, Stuart Seropian, MD, Alfred I Lee, MD PhD, Tara Anderson, PA, Natalia Neparidze, MD

Blood (2019) 134 (Supplement_1): 5569.

https://doi.org/10.1182/blood-2019-130134

Published: 2019

Journal Articles

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Blood (2019) 134 (Supplement_1): 3140.

https://doi.org/10.1182/blood-2019-129038

Published: 2019

Journal Articles

Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism

Blood (2018) 132 (Supplement 1): 2506.

https://doi.org/10.1182/blood-2018-99-115529

Published: 2018

NARROW

Isatuximab in Relapsed AL Amyloidosis: Results of a Prospective Phase II Trial (SWOG S1702)

Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma

The Association between Glucagon-like Peptide-1 Receptor Agonist and Major Adverse Cardiac and Cerebrovascular Events in Monoclonal Gammopathy of Undetermined Significance: A Propensity-Score Analysis

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed By Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Evaluation of Metabolic Profile in Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma

Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Defining Ferritin Clinical Decision Limits to Improve Diagnosis and Treatment of Iron Deficiency: A Modified Delphi Study

Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience

Advanced Imaging and Targeted Myeloma Lesion Biopsies to Enhance Global Response Assessment and Evaluate Spatial Heterogeneity in Multiple Myeloma

A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis (SWOG S1702; NCT#03499808)

Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience

Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience

Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacytomas

Whole Exome Sequencing and Extended Thrombophilia Testing in Patients with Venous Thromboembolism

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only